Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the li...
SCYNEXIS, Inc. is a biotechnology company commi...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...
Sinovac Biotech Ltd. is a China-based biopharma...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...
We are a clinical stage biopharmaceutical compa...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Join the National Investor Network and get the latest information with your interests in mind.